Abstract CT166: Pretreatment (PreTx) immune cell phenotypes in peripheral blood associated with the tumor immune contexture, product attributes, and durable clinical efficacy in patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel)
Justin A. Budka(Gilead Sciences (United Kingdom)), Adrian Bot(Unknown), Nathalie Scholler(Gilead Sciences (United States)), Frederick L. Locke(Moffitt Cancer Center), Vicki Plaks(Johnson & Johnson (United States)), Caron A. Jacobson(Dana-Farber Cancer Institute), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Jérôme Galon(Délégation Paris 5), Lazaros J. Lekakis(University of Miami Hospital), David B. Miklos(Stanford University), Armin Ghobadi(Washington University in St. Louis), Yi Lin, Zixing Wang, Justin Chou, Francesca Milletti, John M. Rossi(Amgen (United States)), Zahid Bashir(AstraZeneca (United Kingdom))
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k